Sign in
Taking people in South KoreaNo phase

Testing CKDB001 for early Alzheimer's disease

Tests the drug CKDB001 in people with early Alzheimer's disease.

Key facts

Who runs it
CKD Bio Corporation
Where
Gyeonggi-do and Seoul, South KoreaSee the 2 sites
Trial code
Registry title
Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
Status
Recruiting
People taking part
60 people, planned
Started
23 Feb 2026
Expected to end
31 May 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • L. lactis CKDB001
  • Placebo
Record updated
30 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 55 to 85 with early Alzheimer's disease and a positive amyloid PET scan.

Age
55 to 85 years
Sex
Men and women can join.
Disease stage
Early Alzheimer's disease: K-MMSE score of 20 to 28, global CDR score of 0.5 to 1, and CDR Memory Box score of 0.5 or greater.
Earlier treatment
No disease-modifying therapy for Alzheimer's within 1 year before screening. No new or changed dementia symptom treatment within 12 weeks before screening.
Biomarker or test result
Positive amyloid on a PET scan.

Main reasons for not taking part

  • Other diseases that could affect thinking tests, such as a history of CNS disease
  • History of seizure disorder or epilepsy
  • Alcohol or substance abuse or dependence
  • Cancer diagnosed or recurring within 5 years before screening
  • Major cardiovascular event within 12 months before screening

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Male and female adults aged ≥55 and ≤85 years at the time of written consent
  • Subjects with a Korean Mini-Mental State Examination (K-MMSE) score of 20 to 28
  • Have a global Clinical Dementia Rating (CDR) score of 0.5 to 1 and a CDR Memory Box score of 0.5 or greater
  • Subjects who test positive for amyloid on Positron Emission Tomography (PET)

Who cannot take part

  • History of a major cardiovascular event within 12 months prior to screening
  • Severe or active infectious disease requiring treatment with antibiotics or antivirals within 4 weeks prior to randomization, or expected to require such treatment during the study period
  • Clinically significant gastrointestinal disorders within 3 months prior to screening, or conditions that may lead to malabsorption
  • Treatment with any disease-modifying therapy for Alzheimer's disease within 1 year prior to screening
  • Initiation or dosage/regimen changes of symptomatic treatments for dementia within 12 weeks prior to screening
  • Chronic use of medications acting on the CNS or those that may affect cognitive function within 8 weeks prior to screening
  • Regular use of medications that may alter the gut microbiota within 4 weeks prior to screening
  • Subjects with clinically significant diseases other than Alzheimer's disease that may confound cognitive assessment; History of central nervous system (CNS) diseases; Active central nervous system (CNS) infection capable of affecting cognitive function, or a history of infection resulting in neurological sequelae; Structural brain abnormalities identified on screening MRI that could account for cognitive impairment; Abnormal thyroid function identified at screening; Vitamin B12 deficiency identified at screening
  • History of seizure disorder or epilepsy
  • History of psychiatric disorders, including schizophrenia, bipolar disorder, or clinically significant major depressive disorder, with current active symptoms
  • History of malignancy diagnosed or recurrent within 5 years prior to screening
  • Cardiovascular disease requiring the administration of anticoagulants
  • History or suspicion of alcohol or substance abuse/dependence

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 55 and 85 years old?

Where in South Korea

  • Yonsei University Yongin Severance HospitalGyeonggi-do, South KoreaContact: Bisong KimTaking people
  • Yonsei University Severance HospitalSeoul, South KoreaContact: Bisong KimTaking people

About the trial

What the trial wants to find out

Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease

The 2 groups in the trial

  • L. lactis CKDB001Existing treatment, for comparison
  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
Plain-language title
Testing CKDB001 for early Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT07496021, who can take part
Record updated
30 March 2026